Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Published 29 October 2009, doi:10.1136/bmj.b4444
Cite this as: BMJ 2009;339:b4444
Tony Delamothe, deputy editor, BMJ
tdelamothe@bmj.com
| The first 150 words of the full text of this article appear below. |
First, the good news on transparency. Drug company Merck is following Eli Lillys lead by publishing details of fees paid to experts for speaking on behalf of the company or its products (doi:10.1136/bmj.b4409). GlaxoSmithKline and Pfizer have promised to follow suit. If drug companies were also to publish details of grants made to patient groups, along with the raw data from their research studies, then truly we would have entered a golden age.
The bad news on transparency is that certain NHS trusts idea of a golden age is one where tongues can be ripped out and mouths stitched up. Jonathan Gornall documents the lengths to which Liverpool Womens NHS Foundation Trust went to stop senior consultant Peter Bousfield from going public with his concerns about management and patient safety (doi:10.1136/bmj.b3202). Part of its armoury was to incorporate a gagging clause into his termination agreement. Too
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
StumbleUpon
Technorati What's this?
Read all Rapid Responses